About us
About the Access Campaign

Our 2022 wishlist

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Active campaigns

No Patents in a Pandemic

20 years of Advocacy in Action

Share the Tech - Save Lives

Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

About us
About the Access Campaign

Our 2022 wishlist

Media room

Latest news

Jobs
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Our work
COVID-19

Explainer: A bold proposal at the WTO by India and South Africa

Diabetes

Drug-resistant infections

HIV/AIDS

Hepatitis C

Hypertension

Patents and intellectual property

The Patent Oppositions Database

Research and development

Spotlight on: the Big Pharma double-dip

Transparency Matters: Clinical Trials Costs

Tropical and neglected diseases

Spotlight on: Snakebite

Tuberculosis

Vaccines

Explainer: COVID-19 vaccines - Recommendations for equitable access
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Get involved
Active campaigns

No Patents in a Pandemic

20 years of Advocacy in Action

Share the Tech - Save Lives

Campaign success stories

#NoMoreTears Johnson & Johnson Can you hear us?

Novartis 'Drop the case'

Trans-pacific Partnership (TPP)
Take Action

Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.
Resources
Press releases

Statements

Letters

Opinion articles

Feature stories

Interviews

Blog

Newsletters

Publications

Research articles

Topic overview pages

Spotlight pages

Videos

Photo stories

Infographics

Events
Get Involved!
Sign up to stay updated and find out how you can get involved.

Email Address

Data protection consent

I want to receive emails from MSF and I have read and agree with the privacy policy.

Medicines shouldn’t be a luxury Take action!

Video |

15 February 2020

Big pharma is double dipping

1 min

RESEARCH AND DEVELOPMENT

Medicines made with help from OUR taxes should be accessible to EVERYONE who needs them.

SHARE this video and tell our leaders to stand up to Big Pharma’s double-dip profiteering.

Read, watch, share

Clinical evaluation research in Mali

Statement |

17 November 2022

Research and development

MSF publishes first Clinical Trial Transparency Policy

5 min

How can disclosing clinical trial costs increase access to medical products?

Events |

17 November 2022

Research and development

How can disclosing clinical trial costs increase access to medical products?

Report Cover image

Technical brief |

11 November 2022

Research and development

MSF Clinical Trial Transparency Policy

Report cover image

Technical brief |

17 October 2022

Research and development

Roundtable: How Can Disclosing Clinical Trial Costs Increase Access to Medical Products?

Cabotegravir is a long-acting antiretroviral medicine used as for HIV prevention in people vulnerable to infection. © Isabel Corthier

Blog |

05 October 2022

Research and development

South Africa can and must demand better deals for drug clinical trials — lives depend on it

How can disclosing clinical trial costs increase access to medical products?

Events

Research and development

Roundtable series: How can disclosing clinical trial costs increase access to medical products

2 min

Report cover image

Technical brief |

10 May 2022

Research and development

MSF comments on the clinical trial resolution at the 75th World Health Assembly

Din Savorn, 50, has his blood pressure taken by MSF nurse Em Thyda at the MSF Hepatitis C clinic at Preah Kossamak Hospital in Phnom Penh, Cambodia, 20, April 2017.

Blog |

23 September 2020

Research and development

Italy

Transparency matters: Italy moves against the secrecy surrounding the cost of medicines